Hormonal
GLP-1 receptor agonists induce weight loss primarily through central nervous system signaling to the arcuate nucleus (specifically POMC/CART neurons) rather than peripheral mechanisms like gastric emptying.
GLP-1 medications work by signaling to your brain's appetite centers (specifically the arcuate nucleus) to reduce food intake, rather than just slowing digestion. This central mechanism is why they are effective for weight loss even when side effects like nausea subside.
Sisley et al. reveal that GLP-1R agonist–induced weight loss requires GLP-1Rs in the CNS... Secher et al. reveal that a small peptide GLP-1R agonist penetrates the brain and activates a subset of GLP-1R–expressing neurons in the arcuate nucleus to produce weight loss.
Why this rating
Based on high-quality animal studies (knockout mice, lesion studies) and referenced human trials, though direct human CNS imaging of this specific pathway is limited in the text.
Source
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
Laurie L. Baggio et al. · Journal of Clinical Investigation · 2014
DOI 10.1172/jci78371
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →